COVID-19 Resources: Guidance for Chan Researchers

Featured news and announcements

FAS Research Computing (FASRC) has offered to provide enhanced support to Harvard Chan School research related to COVID-19. Examples of support include help with workflow automation to improve efficiency for COVID-19 data analysis, and prioritized assistance for virtual machine requests for hosting a COVID-19 analytic tools website. For more information, please contact the FASRC team via email or attend one of their virtual office hours which are held weekly on Wednesdays from 12 PM to 3 PM.

Have you donated personal protective equipment, lab equipment, lab supplies, or travel costs to support COVID-patient care, etc.? If so, NIH funding ICs will consider administrative supplements to support existing resources that were diverted due to COVID-19. Please email Elizabeth Sylvester at esylvester@hsph.harvard.edu for next steps.

COVID FAQs and new funding opportunities for the period 4/07/20 – 04/13/20

As COVID-19 spreads across the globe, new research funding opportunities are cropping up, along with questions regarding how COVID-19-related disruptions to research might affect current federal funding. Answers to many of those questions and information on a variety of new funding opportunities is provided by clicking on the related link below:

1. New Covid-19 research funding opportunities
2. COVID-19 related research news and policy updates
3. Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19
4. Free access and free services for researchers related to COVID-19
5. COVID-19 news by Chan faculty

1. COVID-19 research funding opportunities

Internal COVID-19 Funding Announcements

Non-federal COVID-19 Funding Announcements

*NEW: Fast Grants: Fast Funding for COVID-19 Science
Deadline: Not announced
These grants are for scientists at an academic institution currently working on a COVID-19 related project and in need of funding. Fast Grants are $10k to $500k and decisions are made in under 48 hours.

*NEW: Harrington Scholar Award for Coronavirus: Advancing Therapies for Treating Coronavirus and Future Deadly Viruses
Deadline: April 30, 2020
This award provides funding and expert guidance and oversight in all aspects of drug/therapeutics development, while taking no rights to intellectual property, which is retained by the award recipient and their institution.

*NEW: Pfizer: COVID-19 Independent Medical Education Grants*
**Deadline: May 22, 2020**
Pfizer supports educational programs for healthcare providers focused on the recognition, diagnosis, treatment, and overall care management of patients with COVID-19, especially programs that include tools designed to help HCP’s educate patients and caregivers on the disease state, preventative measures, and emerging strategies for COVID-19 treatment.

*NEW: Pfizer: Quality & Process Improvement Grants*
**Deadline: May 22, 2020**
The grant provides support to hospitals or healthcare systems so that they may evaluate and improve their systems-of-care for COVID-19 patients. Funds can be used for staff training or clinical process improvement. While hospitals are dealing with the urgent care of patients with COVID-19, these grants can be used to address procedural challenges and needs. Quality improvement grants can also be used to help facilitate the sharing and exchange of best practices across hospital systems or geographic regions. Our goal is that the quality or process of care of patients will be improved with this additional funding support.

*NEW: Coalition for Epidemic Preparedness Innovation: Multi-purpose platform technologies for rapid response against emerging infectious diseases*
**Deadline: April 19, 2020**
CEPI is requesting information from entities able to serve as possible sponsors or to provide operational trial support (Clinical Research Organizations) for clinical trials involving vaccine candidates against COVID-19.

*NEW: Antler: COVID 19 Calls*
**Deadline: April 15, 2020**
This call is for startups tackling the Covid-19 outbreak to apply for funding. If you have an idea that can chart the path to recovery in: Mitigation (e.g. masks, contact tracing, surveillance, data infrastructure), Medical Equipment (e.g. test kits, protective devices, ventilators); Remote Health (e.g. telehealth, remote patient monitoring, symptom checkers); and Digital Tools (e.g. remote work, smart delivery, e-learning).

**Russel Sage Foundation: COVID-19 Research Grants**
**Deadline: May 21, 2020**
The foundation funds research that analyzes social, political, economic, or psychological disruptions resulting from the coronavirus crisis that affect social and living conditions in the United States. All LOIs must focus on issues related to the foundation’s core program areas and special initiatives: Behavioral Economics; Decision-Making and Human Behavior in Context; Future of Work; Race, Ethnicity, and Immigration; Social, Political, and Economic Inequality.

**Mozilla: COVID-19 Solutions Fund**
**Deadline: Rolling**
The fund will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open
source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related

**California Institute for Regenerative Medicine (CIRM)**
Deadline: Open on a bi-monthly basis.
The CIRM has allocated $5 million in funding for peer-reviewed regenerative medicine and stem cell research that could quickly advance treatments for COVID-19. Support is provided for promising discovery, preclinical, and clinical trial stage projects.

**Elhra: Research to Support COVID-19 Response in Humanitarian Settings**
Deadlines: April 20, and May 4, 2020
Elhra is launching an urgent funding call for research proposals to support the COVID-19 response in humanitarian settings. The call aims to fund public health research that will produce robust findings that will contribute to the effectiveness of the current humanitarian response and increase the evidence base for future responses to similar infectious disease outbreaks.

**IBM: Call for Code Global Challenge**
Deadline: July 31, 2020
The Call for Code Global Challenge, an initiative of IBM, asks the world's developers to build solutions for COVID-19 and climate change. Interests include crisis communication, remote education, and community cooperation.

**Nellie Mae Education Foundation: Racism is a Virus Too**
Deadline: Rolling basis until resources are exhausted
The Nellie Mae Education Foundation created a rapid response fund to respond to the hate crimes and bias against Asian American communities in New England resulting from COVID-19.

**Omidyar Network India: Rapid Response Funding for COVID-19**
Deadline: Not announced
The Omidyar Network India has announced a rapid response window to fund proposals that support the lower 60% of India’s income distribution in managing and mitigating the challenges that come with Covid-19. Support is provided for initiatives that strengthen containment, detection and treatment, support crisis management capabilities, and enhance resilience and recovery in the wake of Covid-19.

**Open Road Alliance**
Deadline: Not announced
The Open Road Alliance is offering charitable grants to organizations responding directly to COVID-19, with priority given to organizations and activities that have a clear and direct role in ‘flattening the curve’ and thus limiting, shortening, or minimizing the economic and social, as well as health effects of the pandemic. Loans are also available to organizations affected by COVID-19, including those with lost event revenue, those delivering vital community services, and social enterprises.

**British Society for Antimicrobial Chemotherapy: COVID-19 funding call**
Deadline: April 17, 2020
This call supports researchers in better understanding and addressing COVID-19 outbreak.

**Innovative Medicines Initiative**
This Initiative is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations. The initiative seeks to involve a broader range of partners, including mid-sized companies, from different sectors e.g. biomedical imaging, medical information technology, diagnostic and/or animal health industries.

**Amazon Web Services (AWS): Diagnostic Development Initiative**  
**Deadline:** June 30, 2020  
This Initiative provides support for innovation in rapid and accurate patient testing for 2019 novel coronavirus (COVID-19), and other diagnostic solutions to mitigate future outbreaks.

**Novartis: COVID-19 Response Fund**  
**Deadline:** TBA  
These grants will support public health initiatives designed to help communities manage challenges posed by the pandemic focused on but not limited to the following areas: 1. Strengthening local and national healthcare infrastructure including funding of additional medical personnel, sourcing of medicines and medical equipment; 2. Establishing digital platforms for COVID-19 related data collection, remote delivery of healthcare and effective dissemination of important public health information; and 3. Creating new or enhancing new community health programs specific to the pandemic response.

**Enhancing Learning and Research for Humanitarian Assistance: Research for Health in Humanitarian Crises (R2HC) Programme**  
**Deadline:** July 16, 2020  
This program aims to improve health outcomes by strengthening the evidence base for public health interventions in humanitarian crises.

**Medical CBRN Defense Consortium: CoV Pandemic Response**  
**Deadline:** Submissions will be accepted through May 31.  
This RFI seeks white papers in response to the novel Coronavirus (2019-nCoV) pandemic in the United States in the following areas: diagnostics/monitoring; surveillance; information systems and technology; therapeutics (drugs and/or drug/device combinations, or platforms currently under development); prophylactics; and clinical trials.

**Bill & Melinda Gates Foundation, Wellcome and Mastercard: COVID-19 Therapeutics Accelerator**  
**Deadline:** TBA  
This initiative speeds development and access to therapies for COVID-19 by coordinate R&D efforts and removing barriers to drug development and scale-up to address the epidemic.

**The American Heart Association: Rapid Response Grant COVID-19 and Its Cardiovascular Impact**  
The AHA invites cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19.

**Massachusetts Institute of Technology Solve: Health Security and Pandemics Challenge**  
**Deadline:** June 18, 2020  
MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers.
Massachusetts Institute of Technology Solve: The Elevate Prize for Health Security

The Elevate Prize for Health Security will be awarded to one Solver team from the Health Security & Pandemics Challenge. This prize is supported by The Elevate Prize Foundation, which recognizes that there are heroes all over the world who are putting their health and safety at risk to treat those who are infected and to save lives. Now more than ever, it is critical to recognize and uplift those who are elevating humanity. The Solver team that is selected will be named an Elevate Prize Global Hero and will participate in both the MIT Solver program and the Elevate Prize Global Heroes program, receiving a minimum of $300,000 over two years and ongoing support from The Elevate Prize Foundation and MIT Solve.

Federal COVID-19 Funding Announcements

Deadline: June 01, 2020 (first upcoming)
For research on how coinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent for Coronavirus Disease 2019 (COVID-19), might affect HIV-associated comorbidities, coinfections, and complications (CCCs) within its mission.

*NEW: Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (NOT-MD-20-019)
Deadline: Rolling - May 01, 2020-May 2, 2021
The National Institute on Minority Health and Health Disparities seeks research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

*NEW: Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-017)
Deadline: Rolling - May 15, 2020- January 26, 2022
For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

*NEW: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-016)
For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

*NEW: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus (NOT-MH-20-047)
Deadline: Rolling - March 27, 2020-April 16, 2021
For research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.

*NEW: Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-CA-20-043)
Deadline: Rolling - April 14, 2020-June 26, 2020
This NOSI encourage applications from small businesses with NCI-funded active NCI SBIR/STTR awards that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19) in cancer patients, cancer survivors, and in the general population.

Deadline: Rolling - May 01, 2020-May 04, 2021
For research to understand the impact of environmental exposures on (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus. NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

*NEW: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-DK-20-018)
Deadline: June 01, 2020 (first upcoming)
NIDDK is particularly interested in projects focusing on the direct action of the virus on kidney, gastrointestinal tract function, and the endocrine/metabolic system, and the collection of biosamples that will inform the understanding of renal, gastrointestinal, and endocrine/metabolic sequelae of viral infection. Pilot clinical studies (observational and interventional) that support the understanding or treatment of COVID-19-related diseases within the mission of the NIDDK are also of interest.

*NEW: Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) (NOT-DC-20-004)
Deadline: Rolling from April 07, 2020 to June 02, 2020
For research on SARS-CoV-2 and COVID-19 in relation to NIDCD’s scientific mission areas of hearing, balance, taste, smell, voice, speech and language.

*NEW: BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement
Deadline: June 30, 2020
BAA seeks abstract submissions for the following: Diagnostic assays, screening and model development, vaccines, advanced manufacturing.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) (NOT-AI-20-030)
Deadline: varies
NIAID and NIGMS are offering Competitive Revisions to active grants addressing research objectives focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against
2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.

**Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed) (NOT-ES-20-014)**
Deadline: Varies
NIEHS WTP grantees are re-programming existing extramural funds to provide Coronavirus preparedness training to their worker populations. The newly proposed training under this announcement would be utilized to award supplemental funding to expand these ongoing Coronavirus response training efforts.

**Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-20-012)**
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.

Deadline: June 2020.
The Agency for Healthcare Research and Quality intends to publish a new funding opportunity announcement using the R01 mechanism to support novel, high-impact studies evaluating health system and healthcare professional responsiveness to COVID-19. This Notice is being provided to allow potential applicants sufficient time to develop responsive applications.

**Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19**
Deadline: mid-May
Agency for Healthcare Research and Quality intends to publish a new funding notice allowing requests for urgent revision supplements to existing AHRQ grants and cooperative agreements to address health system responsiveness to COVID-19. AHRQ intends to allow grantees with active AHRQ research grants to submit requests for competitive revision supplements to address timely health system and healthcare professional response to COVID-19.

**Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-HG-20-030)**
Deadline: varies
This NOSI encourages the submission of applications for Competitive Revisions to support genomic research on SARS-CoV-2 and COVID-19 disease. Of particular interest are genomic studies utilizing generalized approaches that take advantage of human research or model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to guide and inform future efforts to diagnose, prevent, mitigate, or treat this viral infection.

**Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)**
Deadline: varies
NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address the following NIA division research interests: Aging Biology; Neuroscience; Geriatrics and Clinical Gerontology; and Behavioral and Social Research.

HHS: Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)
Deadline: June 16, 2020
The U34 award will support clinical trial planning. This includes collection of feasibility data and complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. The clinical trial that is being planned must aim to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase I trial for a different indication by the time a clinical trial planning award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair.

DoD: Newton Award for Transformative Ideas during the COVID-19 Pandemic
Deadline: May 15, 2020
This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. Proposals should aim to produce novel conceptual frameworks or theory-based approaches that present disruptive ways of thinking about fundamental scientific problems that have evaded resolution, propose new, paradigm-shifting scientific directions, and/or address fundamental and important questions that are argued to be undervalued by the scientific community. Approaches can include analytical reasoning, calculations, simulations, and thought experiments. While data collection and production are therefore allowed, all supporting data should be generated without the use of laboratory-based experimentation or instrumentation.

Deadline: varies
This NOSI highlights the urgent need for research on the 2019 novel Coronavirus, particularly in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
Deadline: varies
There is an urgent public health need to better understand SARS-CoV-2, particularly to improve the predictive quality of existing models of spread, diagnostics for measurement of transmission, susceptibility and recovery, and development of therapeutic interventions. NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:
- Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
- Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
- Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only)

**Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047)**
Deadline: varies
NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications in response to this NOSI must be submitted using the following targeted funding opportunity: **PA-18-935** Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional); and **PA-18-591** Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

**Notice of Special Interest (NOSI) Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need (NOT-R-20-111)**
Deadline: varies
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through **PA-18-591**), Collaborative Innovation Awards to U01 and R21 awards (through **PAR-19-099** and **PAR-19-100**, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through **PAR-19-337**).

**Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)**
NIGMS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19).

**HHS: Strengthening Global Field Epidemiology Training Program (FETP) Network**
Deadline: April 27, 2020
Globally there is insufficient capacity to adequately prevent, detect and respond to public health issues. Field epidemiology networks have been assisting countries with developing and strengthening their public health workforce and are essential to strengthening health systems worldwide and achieving global public health objectives. The purpose of this announcement is to partner with an established Global Network and at least two established Regional Networks of public health training in target regions (Sub-Saharan Africa and Asia Pacific) to strengthen and sustain applied epidemiology.

**HHS: Global Health Security Partner Enhancement: Expanding Efforts to Improve Surveillance and Laboratory Data Interoperability**
Deadline: May 4, 2020
CDC seeks to work with partner countries and other USG agencies in a collaborative effort to achieve specific goals in three focus areas: 1) Preventing avoidable epidemics 2) Detecting threats early 3) Responding rapidly and effectively

HHS: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)
Deadline: September 25, 2020
This FOA solicits competitive revision applications to support the demonstration, and/or dissemination, and/or implementation of highly innovative and impactful translational science projects that address the goals of the CTSA Program that are beyond the original scope of the approved project. Projects will be considered for an increase in support for an expansion of the parent project’s approved scope.

HHS: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)
Deadline: July 11, 2019
Thus opportunity supports investigators from three or more CTSA Program hub institutions to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination within outside the CTSA Program consortium if appropriate.

HHS: Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)
Deadline: June 20, 2020
This opportunity solicits research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens.

NIH - NIAID and NIGMS: Notice of Special Interest regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Deadline: Applications accepted on a rolling basis from February 6, 2020 through February 6, 2021
NIAID and NIGMS highlight the urgent need for research on the 2019 novel Coronavirus: NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV; and NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronavirus and related pathogens.

NIH – NHLBI: Notice of Special Interest: Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019
Deadline: October 6, 2020
NHLBI is issuing this Notice of Special Interest to highlight the urgent need for research on Coronavirus Disease 2019 and on biological effects of its causative agent, the severe acute respiratory syndrome 2. Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

NIH: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NIH is taking several approaches to support new research in response to severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019. If you are a grantee currently supported by active NIH funding, you may be eligible to apply for an administrative supplement to support SARS-CoV-2/COVID-2019 research.

NIH: Urgent Award Mechanism, Competitive Revisions to Existing NIH Grants
Deadline: varies
The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

NIH – NIDA: Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Deadline: Applications will be accepted on a rolling basis through March 31, 2021
NIDA is issuing this notice to highlight the urgent need for research on the 2019 Novel Coronavirus. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

NSF: Dear Colleague Letter 20-052 re Corona Virus Proposals
Deadline: Varies
NSF is accepting proposals to model, track, inform, educate, and prevent the spread of Coronavirus through its existing funding opportunities. NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Visit NSF, Dear Colleague 20-053 for Coronavirus proposal FAQs and conditions and process for proposal deadline extension.

NSF-Office of Advanced Cyberinfrastructure (OAC), Dear Colleague Letter 20-055
Deadline: varies
OAC is inviting Rapid Response Research (RAPID) funding mechanism proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

HHS: Development of Medical Products for Novel Coronavirus: Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
Deadline: October 31, 2020
This amendment solicits proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals.

HHS/CDC: Prototype Development to Combat Novel Coronavirus Disease COVID-19
Deadline: April 30, 2020
The Government seeks to rapidly accelerate the inquiry, testing, and fielding of new 21st century capabilities, employing novel technologies and approaches to the detection of exposure, prevention, containment and treatment of COVID-19 and future emerging threats.

**DOE: Invitation for COVID-19 Scientific Questions (DOE Resources)**  
Deadline: Ongoing  
The Department encourages scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure. Please send research questions that the scientific community may address with DOE resources by email to SC.DCL@science.doe.gov.

2. **COVID-19 related research news and policy updates**

A few of the provisions in the third COVID-19 relief/response package that might be of particular interest to researchers is below. To read more, please download a section-by-section summary and the legislative text.

- **NIST** - $6 million to provide continuity of operations and to conduct research and measurement science to support the testing and treatment of coronavirus. Page 622 of the legislative text.
- **NSF** - $75 million to support research at molecular, cellular, physiological and ecological levels to better understand coronavirus genetics, modes of action, transmission, virulence, and population dynamics. It is expected that many of these funds will be available through the Rapid Response Research funding mechanism. Read Dear Colleague Letter here. Page 629.
- **DOE Office of Science** - $99.5 million for costs related to equipment, personnel, and operations to support research on the coronavirus, including support to provide access to user facilities. Page 654.
- **EPA S&T** - $1.5 million to support research efforts regarding coronavirus – and specifically, research on methods to reduce risks from environmental transmission via contaminated surfaces. Page 713.
- **CDC** - $4.3 billion to support federal, state, and local public health agencies to prevent, prepare for and respond to the coronavirus. Included in that amount is $500 million for global disease detection and emergency response, $500 million for public health data surveillance and analytics infrastructure modernization, and $300 million for the Infectious Diseases Rapid Response Reserve Fund, which supports immediate response activities during outbreaks. Page 728.
- **NIH** - The bill includes $945 million to support research and expand on prior research plans, including developing an improved understanding of the prevalence of COVID-19, its transmission and the natural history of infection, and novel approaches to diagnosing the disease and past infection, and developing countermeasures for the prevention and treatment of its various stages. Of this total, $103 million is allocated for NHLBI, $706 million NIAID, $60 million NIBIB, $36 million NCATS, $30 million OD, and $10 million for National Library of Medicine. When combined with the first supplemental, Congress has provided $1.78 billion for NIH research on COVID 19. Page 730.
- **BARDA** (Biomedical Advanced Research and Development Authority) - At least $3.5 billion to advance construction, manufacturing, and purchase of vaccines and therapeutics to the American people.
- **NASA** - $60 million to support NASA with resources for operational adjustments associated with mission delays caused by NASA center closures related to coronavirus. Page 628. Also, the package includes a number of health-related authorizations, including the HRSA health professionals and nursing workforce development programs.
3. **Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19**

**NIH**

- *NEW: OHRP Guidance on COVID-19* under Human Subjects and Clinical Trials
- *NEW: notice on Guidance for Cost-Related Flexibilities Available to Support of Competitive Research (SCORE) Award Recipients Affected by COVID-19
- *NEW: Virtual NIH Activities for Trainees Outside the NIH
- **Animal Welfare:** COVID-19 Pandemic Contingency Planning for Animal Care and Use Programs
- **Coronavirus Disease 2019 (COVID-19):** Information for NIH Applicants and Recipients of NIH Funding. The page now includes a link to page update history so you can easily see what’s new.
- **UPDATE:** NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19): applications submitted late for due dates between March 9, 2020, and May 1, 2020, will be accepted through May 1, 2020
- New guidance of flexibilities for awardee, students and conference funding during COVID-19 period
- FAQs including new section on Training, Fellowship and Career Development Awards
- An FAQ to address questions regarding proposal submission and award management
- A lenient late-application policy for those who are unable to meet application deadlines due to the COVID-19 emergency
- NIH grant recipients may extend the final budget period of the approved project on active grants one time for up to 12 months without requesting prior approval from NIH

**Other Federal Guidance**

- **USAMRAA’s Supplemental Guidance on Administrative Flexibilities for Grants and Cooperative Agreements in Response to COVID-19 Pandemic**
  
- **Frequently Asked Questions (FAQs) published by The Department of Defense (DoD).**

4. **Free access and free services for researchers related to COVID-19**

- *NEW: Internal: FAS Research Computing* has offered to provide enhanced support to Harvard Chan School research related to COVID-19. Examples of support include help with workflow automation to improve efficiency for COVID-19 data analysis, and prioritized assistance for virtual machine requests for hosting a COVID-19 analytic tools website. For more information, please contact the FASRC team via email or attend one of their virtual office hours which are held weekly on Wednesdays from 12 PM to 3 PM.
- **Open Research Dataset** (CORD-19) is a resource of over 45,000 scholarly articles, including over 33,000 with full text, about COVID-19, SARS-CoV-2, and related coronaviruses.
- **IBM has resources to share** — like supercomputing power, virus tracking and an AI assistant to answer citizens’ questions.
• LitCovid is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus.
• The National Institute of Allergy and Infectious Diseases (NIAID) has made 2019 SARS-CoV-2 and other Coronavirus strains and reagents available through its BEI Resources Repository.
• The American Journal Experts are offering free language editing and translation services for articles related to coronavirus disease 2019
• Sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak, with NIH as a signatory to the statement Wellcome Trust news, January 31, 2020
• The BMJ: Coronavirus
• Chongqing VIP Information, a Chinese journal database
• Elsevier: Novel coronavirus information center
• The Lancet: COVID-19 resource centre
• New England Journal of Medicine: free Journal content on coronavirus
• Royal Society of Tropical Medicine and Hygiene: Coronavirus free collection
• Springer Nature, the publisher of Nature: Novel coronavirus (SARS-CoV-2 and COVID-19)
• Wiley Online Library: COVID-19 resources and news
• WHO: COVID-19 Course Series - free online courses from OpenWHO

5. COVID-19 news by Chan faculty

• Find the latest COVID news by Chan faculty here.